Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -273136.36% is 16712% below its 5-year average of -1624.65%, near the low end of its 5-year range (-273136.36%–9985.34%).
296.70% below its 12-month average of -68851.58%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -81305.88%.
EBITDA MARGIN
-273136.36%
EBITDA MARGIN AVG TTM
-68851.58%
EBITDA MARGIN AVG 3Y
-44908.19%
EBITDA MARGIN AVG 5Y
-1624.65%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-296.70%
CURRENT VS 3Y AVG
-508.21%
CURRENT VS 5Y AVG
-16712.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Senti Biosciences, Inc.
Market Cap
$9.72M
EBITDA Margin
-273136.36%
TTM Avg
-68851.58%
3Y Avg
-44908.19%
5Y Avg
-1624.65%
Market Cap
$9.71M
EBITDA Margin
-2995.72%
TTM Avg
-2995.72%
3Y Avg
-2995.72%
5Y Avg
-2995.72%
Market Cap
$9.83M
EBITDA Margin
-32.77%
TTM Avg
-184.94%
3Y Avg
-1690.71%
5Y Avg
-2111.15%
Market Cap
$9.50M
EBITDA Margin
-7418.23%
TTM Avg
-25513.08%
3Y Avg
-14528.12%
5Y Avg
-11171.17%
Market Cap
$10.06M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.04M
EBITDA Margin
-685.63%
TTM Avg
-612.49%
3Y Avg
-514.11%
5Y Avg
-584.57%
Market Cap
$10.13M
EBITDA Margin
-778.88%
TTM Avg
-678.54%
3Y Avg
-485.57%
5Y Avg
-387.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Senti Biosciences, Inc. (SNTI) | $9.72M | -273136.36% | -68851.58% | -44908.19% | -1624.65% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | -2995.72% | -2995.72% | -2995.72% | -2995.72% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | -32.77% | -184.94% | -1690.71% | -2111.15% |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.50M | -7418.23% | -25513.08% | -14528.12% | -11171.17% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | N/A | N/A | N/A |
| Valion Bio, Inc. (VBIO)vs › | $10.04M | -685.63% | -612.49% | -514.11% | -584.57% |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.10M | N/A | N/A | N/A | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | -778.88% | -678.54% | -485.57% | -387.51% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
Gross Margin
-16431.8%
EBITDA Margin
-273136.4%
Operating Margin
-289668.2%
Net Margin
-90116.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -81305.88% |
| 2026-03-31 | -67562.50% |
| 2025-12-31 | -57686.36% |
| 2023-09-30 | -16494.51% |
| 2023-06-30 | -1491.68% |
| 2023-03-31 | -1091.37% |
| 2022-12-31 | 9985.34% |
| 2022-09-30 | -904.82% |
| 2022-06-30 | -1880.51% |
| 2022-03-31 | -973.55% |
| 2021-12-31 | -1242.24% |
| 2021-09-30 | -1139.42% |
| 2021-06-30 | -1013.75% |
| 2021-03-31 | -12468.06% |
| 2020-12-31 | -320800.00% |
